A pharmaceutical player for years, Zhongshan Wanhan Pharmaceuticals Co has pioneered an intelligent manufacturing upgrade path centered on full-chain digital control. Powered by a triple engine of precision testing, intelligent production and independent development, the company redefines affordable medicine through "China-made quality."

In Wanhan's QC laboratory, spanning over 2,600 square meters with more than 50 functional rooms, 4 major testing sections for physicochemical, precision instruments, sample retention and microbiology operate in synergy, safeguarding drug quality across the entire lifecycle.

Within the 6.67-hectare industrial park, Wanhan has allocated 3.33 hectares to build an active pharmaceutical ingredients (APIs) production base, achieving end-to-end supply chain autonomy from raw materials to finished drugs. This positions it among Zhongshan's rare firms with self-developed APIs capabilities.

In terms of R&D, the company invests over 80 million yuan annually and has built a 70-member R&D team. Leveraging a digital R&D platform, it has secured nearly 50 drug approvals and launched the "Wanhan Runjing" eye drops series that covers over 20 products, establishing a unique edge in ophthalmic preparations.

Through national centralized procurement, Wanhan's products are priced at least 80% lower than original drugs, serving over 50 million patients yearly.